Search for Clinical Trial Results

Sponsored By

Angelman Syndrome - 9 Studies Found

Status Study
Completed Study Name: Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
Condition: Sleep Problems
Date: 2013-07-16
Interventions:
  • Drug: Circadin 2 mg First arm

Completed Study Name: Genomic Imprinting and Assisted Reproductive Technologies
Condition:
  • Natural Pregnancy
  • Pregnancy, Ovarian

Date: 2008-10-15
Withdrawn Study Name: An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
Condition: Autism Spectrum Disorder
Date: 2014-08-21
Interventions: Drug: EPI-743 Other Name: Vincerinone TM
Active, not recruiting Study Name: Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Condition: Sleep Disorders
Date: 2013-07-11
Interventions:
  • Drug: Circadin 2/5/10 mg Activ
COMPLETED Study Name: Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
Condition: Angelman Syndrome
Date: 2025-11-04
Interventions: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device.In this study, the testing involved with t
Completed Study Name: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Condition: Angelman Syndrome
Date: 2025-11-04
Interventions: Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.I
COMPLETED Study Name: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Condition: Angelman Syndrome
Date: 2025-11-04
Interventions: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
COMPLETED Study Name: A Study of the Safety and Tolerability of GTX-102 in Children with Angelman Syndrome
Condition: Angelman Syndrome
Date: 2025-11-04
Interventions: antisense oligonucleotide
COMPLETED Study Name: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
Condition: Angelman Syndrome
Date: 2025-11-04
Interventions: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 week